Fc-engineered antibody therapeutics with improved efficacy against COVID-19

Monoclonal antibodies (mAbs) with neutralizing activity against SARS-CoV-2 have demonstrated clinical benefit in cases of mild to moderate SARS-CoV-2 infection, substantially reducing the risk for hospitalization and severe disease(1–4). Treatment generally requires the administration of high doses...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamin, Rachel, Jones, Andrew T, Hoffmann, Hans-Heinrich, Kao, Kevin S, Francis, Rebecca L, Sheahan, Timothy P, Baric, Ralph S, Rice, Charles M, Ravetch, Jeffrey V, Bournazos, Stylianos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168397/
https://www.ncbi.nlm.nih.gov/pubmed/34075373
http://dx.doi.org/10.21203/rs.3.rs-555612/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168397/
https://www.ncbi.nlm.nih.gov/pubmed/34075373
http://dx.doi.org/10.21203/rs.3.rs-555612/v1

Ejemplares similares